Senseonics Holdings Inc (NYSEAMERICAN:SENS) CEO Timothy T. Goodnow acquired 88,500 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were bought at an average price of $1.10 per share, with a total value of $97,350.00.
SENS stock traded down $0.01 during midday trading on Thursday, hitting $1.12. The company’s stock had a trading volume of 38,559 shares, compared to its average volume of 1,812,573. Senseonics Holdings Inc has a 12 month low of $0.92 and a 12 month high of $4.89.
Senseonics (NYSEAMERICAN:SENS) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01). The business had revenue of $4.61 million during the quarter, compared to analyst estimates of $4.53 million. During the same period last year, the firm earned ($0.16) EPS. Senseonics’s revenue for the quarter was up 27.2% compared to the same quarter last year.
Hedge funds have recently bought and sold shares of the business. III Capital Management bought a new position in Senseonics in the 2nd quarter worth approximately $408,000. Bank of America Corp DE boosted its stake in Senseonics by 620.3% in the 4th quarter. Bank of America Corp DE now owns 40,705 shares of the company’s stock worth $106,000 after purchasing an additional 35,054 shares during the period. Creative Planning bought a new position in Senseonics in the 1st quarter worth approximately $34,000. Raymond James & Associates boosted its stake in Senseonics by 7.2% in the 1st quarter. Raymond James & Associates now owns 910,947 shares of the company’s stock worth $2,232,000 after purchasing an additional 61,483 shares during the period. Finally, BNP Paribas Arbitrage SA bought a new position in Senseonics in the 1st quarter worth approximately $43,000. Institutional investors and hedge funds own 30.66% of the company’s stock.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Further Reading: Hedge Funds – Risk or Reward?
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.